دورية أكاديمية
أعرض في EDS

Immunomodulatory and Anticancer Effects of Fridericia chica Extract-Loaded Nanocapsules in Myeloid Leukemia.

التفاصيل البيبلوغرافية
العنوان: Immunomodulatory and Anticancer Effects of Fridericia chica Extract-Loaded Nanocapsules in Myeloid Leukemia.
المؤلفون: de Freitas Gomes A; Post-Graduate Program in Hematology, The State University of Amazon (UEA), Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.; Laboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil., Batalha ADSJ; Laboratory of Innovative Therapies, Federal University of Amazonas (UFAM)), Manaus 69077-000, AM, Brazil.; Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas (UFAM), Manaus 69077-000, AM, Brazil., de Castro Alves CE; Laboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil., Galvão de Azevedo R; Laboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil.; Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas (UFAM), Manaus 69077-000, AM, Brazil., Rodriguez Amado JR; Post-Graduate Program in Health Sciences, Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados 79825-070, MS, Brazil., Pereira de Souza T; Post-Graduate Program in Pharmaceutical Innovation, Federal University of Amazonas (UFAM)), Manaus 69077-000, AM, Brazil., Koolen HHF; Research Group in Metabolomics and Mass Spectrometry, Amazonas State University (UEA), Manaus 690065-130, AM, Brazil., da Silva FMA; Multidisciplinary Support Center, Federal University of Amazonas (UFAM)), Manaus 69080-900, AM, Brazil., Chaves FCM; Embrapa Western Amazonia, Manaus 69010-970, AM, Brazil., Florentino Neto S; Post-Graduate Program in Health Sciences, Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados 79825-070, MS, Brazil., Boechat AL; Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas (UFAM), Manaus 69077-000, AM, Brazil., Soares Pontes G; Post-Graduate Program in Hematology, The State University of Amazon (UEA), Foundation of Hematology and Hemotherapy of Amazonas, Manaus 69050-010, AM, Brazil.; Laboratory of Virology and Immunology, National Institute of Amazonian Research (INPA), Manaus 69067-375, AM, Brazil.; Post-Graduate Program in Basic and Applied Immunology, Institute of Biological Science, Federal University of Amazonas (UFAM), Manaus 69077-000, AM, Brazil.
المصدر: Pharmaceutics [Pharmaceutics] 2024 Jun 18; Vol. 16 (6). Date of Electronic Publication: 2024 Jun 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Nanocapsules provide selective delivery and increase the bioavailability of bioactive compounds. In this study, we examined the anticancer and immunomodulatory potential of Fridericia chica (crajiru) extract encapsulated in nanocapsules targeting myeloid leukemias. Nanocapsules containing crajiru (nanocapsules-CRJ) were prepared via interfacial polymer deposition and solvent displacement. Size and polydispersity were measured by dynamic light scattering. Biological assays were performed on leukemia cell lines HL60 and K562 and on non-cancerous Vero cells and human PBMC. The anticancer activity was evaluated using cytotoxicity and clonogenic assays, while the immunomodulatory activity was evaluated by measuring the levels of pro- and anti-inflammatory cytokines in PBMC supernatants treated with concentrations of nanocapsules-CRJ. Nanocapsules-CRJ exhibited significant cytotoxic activity against HL60 and K562 cells at concentrations ranging from 0.75 to 50 μg/mL, with the greatest reductions in cell viability observed at 50 μg/mL ( p < 0.001 for HL60; p < 0.01 for K562), while not affecting non-cancerous Vero cells and human PBMCs. At concentrations of 25 μg/mL and 50 μg/mL, nanocapsules-CRJ reduced the formation of HL60 and K562 colonies by more than 90% ( p < 0.0001). Additionally, at a concentration of 12 μg/mL, nanocapsules-CRJ induced the production of the cytokines IL-6 ( p = 0.0002), IL-10 ( p = 0.0005), IL-12 ( p = 0.001), and TNF-α ( p = 0.005), indicating their immunomodulatory potential. These findings suggest that nanocapsules-CRJ hold promise as a potential therapeutic agent with both cytotoxic and immunomodulatory properties.
References: J Ethnopharmacol. 2008 Aug 13;118(3):361-6. (PMID: 18573628)
Br J Pharmacol. 2017 Jun;174(11):1226-1243. (PMID: 27646173)
Molecules. 2020 Aug 03;25(15):. (PMID: 32756445)
Cell Rep. 2017 Mar 28;18(13):3204-3218. (PMID: 28355571)
World J Clin Oncol. 2021 Feb 24;12(2):69-94. (PMID: 33680875)
Saudi Pharm J. 2019 Feb;27(2):191-199. (PMID: 30766429)
Nat Prod Res. 2020 Mar;34(5):726-730. (PMID: 30445823)
J Control Release. 2021 Jan 10;329:676-695. (PMID: 33022328)
Int J Biol Macromol. 2022 Nov 1;220:537-572. (PMID: 35987359)
Saudi Pharm J. 2017 Dec;25(8):1158-1168. (PMID: 30166904)
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109742. (PMID: 31349429)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Biochem Pharmacol. 2005 Apr 1;69(7):1009-39. (PMID: 15763539)
J Clin Invest. 2011 Oct;121(10):3846-59. (PMID: 21926464)
Front Immunol. 2020 Oct 15;11:575597. (PMID: 33178203)
Signal Transduct Target Ther. 2020 Dec 18;5(1):288. (PMID: 33335095)
Front Oncol. 2022 Jul 05;12:896426. (PMID: 35865470)
Biomolecules. 2022 Aug 31;12(9):. (PMID: 36139047)
Cancer Immunol Res. 2014 Mar;2(3):194-9. (PMID: 24778315)
Acta Cir Bras. 2019 Dec 09;34(10):e201901001. (PMID: 31826147)
Front Oncol. 2022 Mar 29;12:867655. (PMID: 35425710)
Molecules. 2020 May 01;25(9):. (PMID: 32370100)
Biomed Pharmacother. 2024 May;174:116308. (PMID: 38626517)
J Control Release. 2015 Feb 28;200:138-57. (PMID: 25545217)
Int J Mol Sci. 2019 Sep 23;20(19):. (PMID: 31547612)
Braz J Biol. 2010 Nov;70(4):1065-8. (PMID: 21180915)
Int J Biol Macromol. 2019 Apr 1;126:731-742. (PMID: 30593811)
Mater Sci Eng C Mater Biol Appl. 2015 Feb;47:156-64. (PMID: 25492184)
Biomed Pharmacother. 2021 Jul;139:111656. (PMID: 34243603)
Cytokine. 2021 Jun;142:155508. (PMID: 33810945)
Blood. 1995 Oct 15;86(8):2930-7. (PMID: 7579385)
Int J Nanomedicine. 2015 Jun 09;10:3897-909. (PMID: 26089666)
Int J Hyperthermia. 2013 Aug;29(5):464-73. (PMID: 23862980)
Blood. 2013 Nov 7;122(19):3335-9. (PMID: 24041577)
Cytokine Growth Factor Rev. 2018 Oct;43:8-15. (PMID: 30181021)
J Ethnopharmacol. 2013 Nov 25;150(2):576-82. (PMID: 24070833)
معلومات مُعتمدة: CT&I ÁREAS PRIORITÁRIAS #01.02.016301.03422/2021-03; MAECI#01.02.016301.01582/2022-07 Foundation of the State of Amazonas (FAPEAM); PROCAD AMAZÔNIA 88881.200581/201801 he Coordination of Improvement of Higher Education Personnel (CAPES)
فهرسة مساهمة: Keywords: Fridericia chica; cytotoxicity; immunomodulation; myeloid leukemias; nanocapsules
تواريخ الأحداث: Date Created: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11207419
DOI: 10.3390/pharmaceutics16060828
PMID: 38931948
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics16060828